Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.
Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.
Adaptive Biotechnologies (Nasdaq: ADPT) priced an upsized private offering of $300 million 0% convertible senior notes due 2031 to qualified institutional buyers under Rule 144A. The notes, maturing July 1, 2031, carry an initial conversion price of about $24.11, a 40% premium to the $17.22 share price.
Estimated net proceeds of $290.8 million (up to $334.5 million with the option) are expected to be used for capped call transactions, a $25 million repurchase of 1,451,800 shares, repayment of the OrbiMed Purchase Agreement to enhance financial flexibility, and MRD-related and general corporate purposes.
Adaptive Biotechnologies (Nasdaq: ADPT) plans to separate its MRD and Immune Medicine businesses. The company is evaluating strategic and structural alternatives for Immune Medicine and expects to determine a preferred separation path by year-end 2026.
MRD has scaled into a profitable, category-leading diagnostics business with expanded reimbursement, strong clinical evidence, and the clonoSEQ platform. Immune Medicine has built a differentiated discovery platform using a large clinically linked immune receptor dataset and AI-driven discovery.
Adaptive Biotechnologies (Nasdaq: ADPT) plans a private offering of $250 million convertible senior notes due 2031, with an option for an additional $37.5 million, to qualified institutional buyers under Rule 144A.
According to Adaptive Biotechnologies, net proceeds will fund capped call transactions, repay the OrbiMed Purchase Agreement, support up to $25 million in share repurchases, and be used for general corporate purposes and MRD business initiatives.
Adaptive Biotechnologies (Nasdaq: ADPT) reports that its NGS-based clonoSEQ MRD test features in 33 presentations at ASCO 2026 and EHA 2026, including one plenary and 14 oral talks.
According to Adaptive Biotechnologies, new data span multiple myeloma, CLL, ALL, and lymphoma, supporting MRD-guided care and research.
Adaptive Biotechnologies (Nasdaq: ADPT) announced participation in two upcoming investor conferences. The company will host 1x1 meetings at the Craig-Hallum 23rd Annual Institutional Investor Conference on May 28 in Minneapolis and present at the William Blair 46th Annual Growth Stock Conference on June 3 at 3:20 p.m. Central Time.
A live and archived webcast of the William Blair presentation will be available in the Investors section of the company website.
Adaptive Biotechnologies (Nasdaq: ADPT) reported Q1 2026 results for the quarter ended March 31, 2026. Revenue was $70.9 million, driven 95% by MRD, with MRD revenue of $67.1 million (up 53% YoY). clonoSEQ test volume rose 41% to 32,595. Q1 net loss was $20.0 million; adjusted EBITDA loss was $2.5 million. Cash, cash equivalents and marketable securities totaled $237.2 million as of March 31, 2026. Full‑year MRD revenue guidance was raised to $260–$270 million; full‑year operating expenses guidance is $350–$360 million.
Adaptive Biotechnologies (Nasdaq: ADPT) will report first quarter 2026 financial results after market close on May 5, 2026. Management will host a live webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET, with archived replay available within 24 hours.
Investors can access live audio via the company’s Investors website.
Adaptive Biotechnologies (Nasdaq: ADPT) reported fourth-quarter revenue of $71.7M and full-year 2025 revenue of $277.0M, a 55% increase year-over-year. The MRD business drove growth, contributing 86% of Q4 revenue and achieving positive Adjusted EBITDA and positive cash flow.
clonoSEQ test volume rose 39% for 2025 to 105,587 tests. Company recognized $19.5M in MRD pharma milestone revenue, signed two immune-receptor data licenses with Pfizer, and received expanded Medicare coverage for clonoSEQ recurrence monitoring in mantle cell lymphoma. 2026 MRD revenue guidance: $255M–$265M.
Adaptive Biotechnologies (Nasdaq: ADPT) will participate in two investor conferences in early 2026: the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UT on Tuesday, February 10, 2026, and a Fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston, MA on Monday, March 2, 2026 at 11:50 a.m. ET.
Interested parties may access live and archived webcasts of both sessions via the Investors section of the company website at www.adaptivebiotech.com.
Adaptive Biotechnologies (Nasdaq: ADPT) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 5, 2026. Management will host a conference call and webcast beginning at 1:30 p.m. PT / 4:30 p.m. ET. Live audio will be available on the company Investors website and the webcast will be archived for replay within 24 hours.
Investors can listen via the company website at www.adaptivebiotech.com and should check the Investors section for the live link and replay.